Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+50.0%
|
-
|
|
Feb 18
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,139
+16.47%
|
-
|
|
Feb 18
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,354
+20.98%
|
-
|
|
Jan 18
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,223
-21.22%
|
$261,366
$42.03 P/Share
|
|
Jan 10
2022
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,896
-1.24%
|
$1,675,840
$40.87 P/Share
|
|
Jan 10
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
19,639
-63.67%
|
$785,560
$40.82 P/Share
|
|
Jan 10
2022
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,639
-62.4%
|
$785,560
$40.89 P/Share
|
|
Jan 10
2022
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,948
-11.56%
|
$837,920
$40.88 P/Share
|
|
Jan 10
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,870
-6.62%
|
$274,800
$40.65 P/Share
|
|
Jan 08
2022
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
41,896
+3.56%
|
-
|
|
Jan 08
2022
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,639
+50.0%
|
-
|
|
Jan 08
2022
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,639
+50.0%
|
-
|
|
Jan 08
2022
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,948
+24.01%
|
-
|
|
Jan 08
2022
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,093
+26.56%
|
-
|
|
Dec 31
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.39%
|
$15,600
$52.34 P/Share
|
|
Dec 31
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
148
+1.65%
|
$7,696
$52.34 P/Share
|
|
Dec 21
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
175,000
-68.01%
|
$8,050,000
$46.41 P/Share
|
|
Dec 21
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+36.78%
|
$2,800,000
$16.72 P/Share
|
|
Dec 21
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
176,863
-64.21%
|
$8,135,698
$46.79 P/Share
|
|
Dec 21
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
176,863
+40.09%
|
$2,652,945
$15.72 P/Share
|
|
Oct 18
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,448
-6.21%
|
$537,920
$40.15 P/Share
|
|
Oct 18
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
8,192
-0.74%
|
$327,680
$40.0 P/Share
|
|
Oct 15
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,448
+18.62%
|
-
|
|
Oct 15
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,075
+0.1%
|
$2,150
$2.84 P/Share
|
|
Oct 15
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,392
-3.54%
|
$1,615,680
$40.0 P/Share
|
|
Oct 14
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,416
-0.12%
|
$56,640
$40.0 P/Share
|
|
Sep 30
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
215
+2.42%
|
$7,955
$37.28 P/Share
|
|
Sep 30
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
422
+0.55%
|
$15,614
$37.28 P/Share
|
|
Sep 30
2021
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
402
+0.41%
|
$14,874
$37.28 P/Share
|
|
Aug 23
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+0.87%
|
$20,000
$2.84 P/Share
|
|
Jun 30
2021
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
367
+0.38%
|
$14,680
$40.82 P/Share
|
|
Jun 30
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
385
+0.5%
|
$15,400
$40.82 P/Share
|
|
Jun 30
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
173
+2.01%
|
$6,920
$40.82 P/Share
|
|
Jun 14
2021
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
18,289
-27.19%
|
$768,138
$42.27 P/Share
|
|
Jun 14
2021
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,000
+22.92%
|
$760,000
$38.35 P/Share
|
|
May 28
2021
|
Christopher D Alafi Director |
SELL
Open market or private sale
|
Indirect |
38,843
-29.02%
|
$1,553,720
$40.12 P/Share
|
|
May 27
2021
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
13,767
+50.0%
|
-
|
|
May 27
2021
|
Rory B Riggs |
BUY
Exercise of conversion of derivative security
|
Direct |
13,767
+15.39%
|
-
|
|
May 27
2021
|
Christopher D Alafi Director |
SELL
Open market or private sale
|
Indirect |
8,482
-5.96%
|
$339,280
$40.01 P/Share
|
|
May 24
2021
|
Christopher D Alafi Director |
SELL
Open market or private sale
|
Indirect |
26,575
-15.73%
|
$1,063,000
$40.47 P/Share
|
|
May 21
2021
|
Christopher D Alafi Director |
SELL
Open market or private sale
|
Indirect |
1,100
-0.65%
|
$44,000
$40.0 P/Share
|
|
Apr 12
2021
|
Joel S Marcus |
SELL
Bona fide gift
|
Indirect |
25,000
-34.59%
|
-
|
|
Mar 31
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
208
+2.45%
|
$6,864
$33.93 P/Share
|
|
Mar 31
2021
|
Christopher D Alafi Director |
BUY
Grant, award, or other acquisition
|
Direct |
464
+0.13%
|
$15,312
$33.93 P/Share
|
|
Mar 31
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
464
+0.74%
|
$15,312
$33.93 P/Share
|
|
Mar 31
2021
|
Richard A Lerner Director |
BUY
Grant, award, or other acquisition
|
Indirect |
442
+0.46%
|
$14,586
$33.93 P/Share
|
|
Mar 02
2021
|
Joel S Marcus |
SELL
Open market or private sale
|
Indirect |
15,250
-17.42%
|
$518,500
$34.93 P/Share
|
|
Mar 02
2021
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,000
+18.6%
|
$520,000
$26.58 P/Share
|
|
Feb 19
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
27,847
-1.2%
|
$1,086,033
$39.09 P/Share
|
|
Feb 19
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
11,139
-95.06%
|
$434,421
$39.09 P/Share
|